A Multicenter, Open-label Study Evaluating the Long-term Safety and Efficacy of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria

This is a multicenter, open-label study to evaluate the long-term safety and efficacy of XH-S003 capsules in PNH patients. About 26 PNH patients who had received and completed XH-S003 study treatment will be enrolled to take XH-S003 capsules orally according to protocol. Eligible subjects can maintain XH-S003 treatment until the end of the study.

NCT Number	NCT07657052
Lead Sponsor	S-INFINITY Pharmaceuticals Co., Ltd
Conditions	Paroxysmal Nocturnal Hemoglobinuria
Enrollment	26 participants
Start Date	2025-08-15
Primary Completion	2029-09-30 (estimated)
Study Completion	2029-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-18